Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss

Indian Journal of Gastroenterology

Volumn 28, Issue 2, 2009, Pages 45-48

  Esmat, G ^a   El Akel, Wafaa ^a   Metwally, M ^b   Soliman, A ^a   Doss, W ^a   Abdel Hamid, M ^c   Kamal, M ^d   Zalata, K ^e   Khattab, H ^a   El Kassas, M ^f   Esmat, M ^f   Hasan, A ^f   El Raziky, M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b BENHA UNIVERSITY   (Egypt)

^c MINIA UNIVERSITY   (Egypt)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e MANSOURA UNIVERSITY   (Egypt)

^f NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

Author keywords

Combination interferon therapy; HCV genotype 4; Obesity; Steatosis; Sustained viral response

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANOREXIA; ARTICLE; BODY MASS; BODY WEIGHT; CORRELATION ANALYSIS; DIABETES MELLITUS; FATTY LIVER; FEMALE; FOLLOW UP; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; BIOPSY; BODY MASS INDEX; DNA, VIRAL; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 73249129434     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: 10.1007/s12664-009-0016-1     Document Type: Article

References (18)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
2. Sim KH, Wojcik JP, Margulies M, Wade J, Heathcote J. Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to interferon therapy. J Viral Hepat 1998;5:249-53.
3. Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S. Interleukin-12 p40lp70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C. J Interferon Cytokine Res 2001:21:453-61.
4. Adinolfi LE, Durante-Mangoni E, Zampino R, Ruggiero G. Review article: hepatitis C virus-associated steatosis-pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 2005;22(Suppl 2):52-5.
5. Hourigan LF, Macdonald GA, Purdie DM, et al. Fibrosis in chronic hepatitis C correlates signifi cantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
6. Guiannini E, Ceppa P, Botta F, et al. Leptin has no role in determining severity o steatosis and fi brosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;95: 3211-7.
7. Bressler BL, Guinidi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatits C. Hepatology 2003;38:639-44.
8. Bjoro K, Bell H, Hellum KB, et al. Effect of combined interferon-alpha inductiontherapy and a ribavirin on chronic hepatitis C infection: a randomized multicenter study. Scand J Gastroenterol 2002;37:226-32.
9. Akuta N, Suzuki F, Suzuki Y, et al. Hepatocyte steatosis is an important predictor of response to interferon monotherapy in Japanese patients infected with HCV genotype 2a: virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005;75:550-8.
10. Seyam MS, Freashwater DA, O'Donnell K, Mutimer DJ. Weight loss during pergylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepat 2005;12:5531-5.
11. Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Gudat F. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
13. Craxi A, Camma C, Giunta M. Defi nition of response to antiviral therapy in chronic hepatitis C. J Hepatol 1999;31 (Suppl 1):160-7.
14. Castera L, Hezade C, Foudot-Thorval R, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004;53:420-4.
15. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic effi cacy? J Hepatol 2001;35:432-3.
16. Giannini E, Ceppa P, Botta F, et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999;19:432-7.
17. Harrison SA, Brunt EM, Qazi RA, et al. Effect of signifi cant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-9.
18. Ramalho F. Hepatitis C virus infection and liver steatosis. Antiviral Res 2003;60:125-7.